Due diligence of a gene therapy to support in-licensing

Challenge: A mid-sized Japanese pharmaceutical company had made the strategic decision to expand their pipeline and geographical footprint by securing global development and commercialization rights...
Learn More

Due diligence of a company's commercial forecasts

Challenge: A private equity investor was considering a transaction involving a speciality pharma company dedicated to pediatric medicines. The target company had successfully launched a major product...
Learn More

Due diligence of a first-in-class agent for Spinocerebellar Ataxia

Challenge: A Chinese biotech company was evaluating a potential in-license product, a first-in-class agent for the treatment of ataxia and tremors in patients with Spinocerebellar Ataxia (SCA). The...
Learn More

Technical & commercial due diligence of two development-stage companies

Challenge: An established Alacrita client building a business in the inhaled therapeutics sector asked us to carry out a technical and commercial due diligence of two development stage companies...
Learn More

J.P. Morgan preparation for a biotech with an AI-approach

Challenge: A biotech company with an AI-approach to developing new TCRs for immunotherapy asked Alacrita to assist in preparations for the J.P. Morgan Healthcare conference.
Learn More

Due diligence for a contract development & manufacturing organization

Challenge: A contract development and manufacturing organization (CDMO) was in negotiations to acquire two manufacturing sites from other companies. Under normal circumstances, the client would have...
Learn More

Triage DD of short bowel syndrome assets

Challenge: For a mid-size European pharma company thinking of entering a new therapeutic area, we conducted ‘Triage’ level due diligence which focused only on publicly available information for three...
Learn More

Valuation of a biotech company using Monte Carlo

Challenge: A biotechnology startup had entered a major licensing deal with Big Pharma and was able to fund operations via the upfront payment rather than needing to raise a Series A. This introduced...
Learn More

Due diligence on a bladder cancer gene therapy

Challenge: A European investment trust was considering an investment in a Phase 3 gene therapy opportunity targeting a niche oncology indication. Owing to the circumstances of the deal, they had less...
Learn More

Analysis of third party valuation for merger

Challenge: Our client, a publicly listed biotech company, was considering a merger with another publicly listed firm. To further initial discussions, a third-party valuation was commissioned on the...
Learn More

US and European partner outreach for Asian pharma companies

Challenge: A South Korean consulting firm required support in exploratory partner outreach in the US and Europe. Alacrita was commissioned to use its expertise in pharma licensing and deal-making in...
Learn More

Valuation of a lead pipeline agent

Challenge: A privately-funded preclinical stage biotech company asked Alacrita for a valuation of their lead pipeline agent for use in discussions with VC investors regarding their next financing...
Learn More